<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849082</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-22863</org_study_id>
    <secondary_id>EORTC-22863</secondary_id>
    <nct_id>NCT00849082</nct_id>
  </id_info>
  <brief_title>Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate Cancer</brief_title>
  <official_title>Phase III Randomized Comparison of Pelvic Radiotherapy Alone vs Pelvic Radiotherapy Plus the LHRH Analogue Goserelin and Cyproterone Acetate in Carcinoma of the Prostate at High Risk for Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high energy x rays to kill tumor cells. This may be an
      effective treatment for prostate cancer. Androgens can cause the growth of prostate cancer
      cells. Antihormone therapy, such as goserelin and cyproterone, may lessen the amount of
      androgens made by the body and reduces the amount of androgens available to the body. It is
      not yet know whether radiation therapy alone is more effective than radiation therapy given
      together with goserelin and cyproterone in treating patients with prostate cancer.

      PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it
      works compared to giving radiation therapy together with goserelin and cyproterone in
      treating patients with prostate cancer that is at high risk for metastasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the ability of adjuvant hormone therapy with an LHRH agonist
      (Goserelin depot) to produce an increased disease-free survival and to prolong overall
      survival when initiated during the first week of radiotherapy in prostatic cancer patients
      with a high risk of developing metastatic disease.

      OUTLINE: Randomized study. Arm I: Radiotherapy. Whole-pelvic irradiation using photons with a
      recommended energy of at least 10 MV (Co60 therapy is acceptable if higher energy
      unavailable). Arm II: Radiotherapy plus 2-Drug Combination Hormonal Therapy. Whole-pelvic
      irradiation as in Arm I; plus Goserelin, ZDX, NSC-606864; Cyproterone acetate, CPTR,
      NSC-81430.

      PROJECTED ACCRUAL: 400 patients will be entered over 5 years. At least 75 patients on each
      arm should be followed until relapse.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1987</start_date>
  <primary_completion_date type="Actual">November 1995</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity/morbidity of treatment,</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Locoregional remission rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to treatment failure</measure>
  </primary_outcome>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyproterone acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven prostatic adenocarcinoma of the following
        TNM stages and WHO grades: T1 or T2 and grade G3 T3 or T4 and any histologic grade No
        evidence of distant metastases No evidence of positive common iliac or para-aortic lymph
        nodes Confirmed by bone scan, chest x-ray, negative ultrasound or CT of the liver, and CT
        of the retroperitoneum and/or bipedal lymphangiography Extraperitoneal pelvic lymph node
        biopsy may be either positive or negative provided stage and grade criteria are met

        PATIENT CHARACTERISTICS: Age: Under 80 Performance status: WHO 0-2 Hematopoietic: Not
        specified Hepatic: Not specified Renal: Not specified Other: No history of second
        malignancy except basal cell skin carcinoma

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy for prostate cancer Endocrine therapy: No prior hormonal therapy for prostate
        cancer Radiotherapy: No prior radiotherapy for prostate cancer Surgery: No prior radical
        prostatectomy No prior transperitoneal lymph node staging
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Bolla, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU de Grenoble - Hopital de la Tronche</affiliation>
  </overall_official>
  <results_reference>
    <citation>Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T, Collette L. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010 Nov;11(11):1066-73. doi: 10.1016/S1470-2045(10)70223-0. Epub 2010 Oct 7.</citation>
    <PMID>20933466</PMID>
  </results_reference>
  <results_reference>
    <citation>Ataman F, Zurlo A, Artignan X, van Tienhoven G, Blank LE, Warde P, Dubois JB, Jeanneret W, Keuppens F, Bernier J, Kuten A, Collette L, Pierart M, Bolla M. Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. Eur J Cancer. 2004 Jul;40(11):1674-81.</citation>
    <PMID>15251156</PMID>
  </results_reference>
  <results_reference>
    <citation>Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002 Jul 13;360(9327):103-6.</citation>
    <PMID>12126818</PMID>
  </results_reference>
  <results_reference>
    <citation>Zurlo A, Collette L, van Tienhoven G, Blank L, Warde P, Dubois J, Jeanneret W, Storme G, Bernier J, Kuten A, Pierart M, Bolla M; EORTC Radiotherapy and Genito-Urinary Tract Cancer Groups. Acute toxicity of conventional radiation therapy for high-risk prostate cancer in EORTC trial 22863. Eur Urol. 2002 Aug;42(2):125-32.</citation>
    <PMID>12160582</PMID>
  </results_reference>
  <results_reference>
    <citation>Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997 Jul 31;337(5):295-300.</citation>
    <PMID>9233866</PMID>
  </results_reference>
  <results_reference>
    <citation>Dusserre A, Garavaglia G, Giraud JY, Bolla M. Quality assurance of the EORTC radiotherapy trial 22863 for prostatic cancer: the dummy run. Radiother Oncol. 1995 Sep;36(3):229-34.</citation>
    <PMID>8532911</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2009</study_first_posted>
  <last_update_submitted>July 10, 2012</last_update_submitted>
  <last_update_submitted_qc>July 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Cyproterone Acetate</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

